This post has been archived and contains information that may be out of date.
CHA is providing members a summary, prepared by Health Policy Alternatives, of the home health prospective payment system final rule for calendar year 2021.
This post has been archived and contains information that may be out of date.
The California Department of Public Health (CDPH) has issued All Facilities Letter (AFL) 20-85, which informs skilled-nursing facilities (SNFs) of the requirement that they have a full-time dedicated infection preventionist, a plan for infection prevention control, and annual training for all health care personnel, as provided in Assembly Bill (AB) 2644.
This post has been archived and contains information that may be out of date.
On Tuesday, the U.S. Supreme Court heard oral arguments in California v. Texas, a case that has the potential to strike down parts, or all, of the Affordable Care Act (ACA).
It’s encouraging that several key justices signaled they would vote to reject the latest challenge, as upending the ACA would devastate Californians who rely on coverage provided under the law’s umbrella. Among the biggest impacts if the law is negated:
This post has been archived and contains information that may be out of date.
Update on Monoclonal Antibody Therapy Authorized for Emergency Use
On Nov. 9, the Food and Drug Administration granted emergency use authorization (EUA) to a monoclonal antibody therapy called bamlanivimab, produced by Eli Lilly and Company, for the treatment of mild to moderate COVID-19. The federal government has purchased 320,000 doses through the end of 2020; the first allocation to California will be 4,040 doses. California is expected to receive allocations each week.
This post has been archived and contains information that may be out of date.
Senate Bill 1237, which the Governor signed into law on Sept. 18, will expand the scope of practice for nurse-midwives in California. On Nov. 30 from 1 to 2 p.m. (PT), CHA will host a webinar where experts will explain current law, changes in the new law, and what compliance looks like, as well as answer participants’ questions. For more information or to register, click here.
This post has been archived and contains information that may be out of date.
CHA has issued a detailed summary, prepared by Health Policy Alternatives, of the proposed rule updating payment methodologies for the Medicare durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) fee schedule for calendar year 2021, as well as Healthcare Common Procedure Coding System (HCPCS) issues.
This post has been archived and contains information that may be out of date.
The Centers for Medicare & Medicaid Services issued the following updates this week:
SNF 3-Day Rule Billing
Home Health Prospective Payment System Rate Update for Calendar Year 2021
Manual Updates Related to the Hospice Election Statement and the Implementation of the Election Statement Addendum
Updates to Skilled Nursing Facility Patient Driven Payment Model Claims
Nov. 19: IPFQR Program FY 2021 Data Review Webinar
This post has been archived and contains information that may be out of date.
The Health & Human Services’ (HHS) Office of Intergovernmental and External Affairs will host an additional webinar on the updated guidance for its interim final rule on COVID-19 data reporting requirements tomorrow, Nov. 13, at 10 a.m. (PT). The webinar will include time for Q&A.
This post has been archived and contains information that may be out of date.
On Nov. 9, CHA issued an Advocacy Alert asking members to reach out to their representatives about helping protect providers with much-needed additional funding and relief during the lame duck congressional session.
This post has been archived and contains information that may be out of date.
Following the approval by the U.S. Food and Drug Administration (FDA) of emergency use authorization for the investigational monoclonal antibody therapy, bamlanivimab, the Centers for Medicare & Medicaid Services (CMS) announced it will cover monoclonal antibody therapies, with no beneficiary cost-sharing for the duration of the COVID-19 public health emergency.